Avidity’s $300M offering; Rapport raises $174M

Plus, news about Replimmune, Novo Nordisk and Biosplice:

Avidity Biosciences is looking for $300M in stock sale: The RNA company is planning a $300 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Genetic Test for Opioid Addiction Risk Should Be Withdrawn, Experts Tell FDA

A group of 31 physicians and researchers called on the FDA to reverse its decision about AvertD, a test that uses DNA to identify whether

April 5, 2024

FDA posts guidance on how to simplify updates to antimicrobial resistance tests

Dive Brief: The Food and Drug Administration has published final guidance on devices for determining the susceptibility of bacterial or fungal pathogens to different antimicrobial

September 29, 2023

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences – Biotech Investments

EQS-News: Formycon AG / Key word(s): Half Year Results/Conference Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences

August 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.